World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Cision PR Newswire by Cision PR Newswire
May 18, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

SOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ — InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company’s Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.

“We are excited to welcome Alec and Mitch to InterVenn’s Board of Directors at a pivotal moment for the company,” said Andrew Quong, Ph.D., Chief Executive Officer of InterVenn Biosciences. “Their combined expertise in diagnostics commercialization, operational scaling, and life sciences financial strategy will help accelerate our mission to bring glycoproteomics into clinical practice and unlock a new frontier in precision medicine.”

Alec Ford has over 30 years of experience in the genomics, pharmaceutical, and biotechnology industries, and has a proven track record driving commercial growth and performance for businesses in highly competitive and regulated biomedical markets. He currently serves as the Chief Executive Officer of Karius, a leader in liquid biopsy for infectious diseases. He was previously the Chief Operating Officer for Myriad Genetics, a molecular diagnostic company. During his time at Myriad, he launched new products and scaled new business units in Women’s Health, Oncology, Urology, and Prenatal screening. Previously, Alec has held leadership positions at Novartis, Sanofi-Aventis, Nektar Therapeutics, and Pfizer. Alec is a founding board member of BioUtah, Utah’s life sciences trade association.

Mitch Levine is an accomplished finance and corporate strategist with extensive leadership experience in the biotechnology and diagnostics sectors. He is currently the Chief Executive Officer of Prenostics. Most recently, Mr. Levine served as CEO and Board Chair of SmartHealth Diagnostics, where he oversaw the development of digital imaging instrumentation and laboratory expansion under CLIA/CAP accreditation. He previously served as Chief Financial Officer at Oncocyte (Nasdaq: OCX), spearheading ten capital raises and three strategic acquisitions. He is an independent director of Codetta BioSciences, serves as Chair of the Board of Directors of Clarus Dx, and was the Board Chair for ImmunoPrecise Antibodies (Nasdaq: IPA). In 2000, he founded Enable Capital Management, providing growth capital to hundreds of companies in the technology and life sciences sectors.

About InterVenn Biosciences

InterVenn Biosciences is advancing precision medicine through glycoproteomics—an innovative approach that reveals critical biological signals traditional genomics and proteomics cannot see.

By leveraging artificial intelligence and deep glycoproteomic analysis, InterVenn maps the glycoprotein control points that orchestrate disease progression, enabling earlier detection, more precise clinical insights, and improved patient outcomes.

InterVenn’s mission is to unlock the full potential of the glycoproteome to transform diagnostics and personalize patient care across women’s health, oncology, and other complex diseases.

To learn more, visit intervenn.com.

Contact
Nick Khadder – (888) 706-1670, Ext. 889
414579@email4pr.com

Cision View original content:https://www.prnewswire.com/news-releases/intervenn-appoints-industry-leaders-alec-ford-and-mitch-levine-to-board-of-directors-302774032.html

SOURCE InterVenn Biosciences

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Hunton Expands Energy and Infrastructure Practices with Addition of Partners Jonathan Brufal in Abu Dhabi and Simon Elliott in Dubai

    0 shares
    Share 0 Tweet 0
  • SOFICO launches SOFICO Intelligence, bringing proactive AI and agentic automation to automotive finance and lease contract management

    0 shares
    Share 0 Tweet 0
  • UN Global Compact Launches Business Integrity Accelerator to Help Companies Fight Corruption

    0 shares
    Share 0 Tweet 0
  • Mantle Marks Major Milestone as $MNT Becomes Available on GMO Coin Following Japan’s Rigorous Asset Review Framework

    0 shares
    Share 0 Tweet 0
  • Stitch Launches Stitch AI, Bringing Agentic AI Directly Into Banking Operations

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler